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With the high initial success rates for coronary angioplasty
that are reported regularly, it has become increasingly
difficult to demonstrate methods or techniques that are able
to provide more beneficial early results than can be
achieved by conventional angioplasty. On the other hand,
the incidence of late restenosis has remained much the same
over the 10 years that angioplasty has been part of clinical
practice, and there is still no proved intervention that
modifies the restenosis process. Therefore, the problem of
restenosis has assumed increasing relevance in determining
the clinical value of coronary angioplasty and, accordingly,
studies that address the problem of restenosis need to
become more exacting.
Studies aimed at reducing the incidence of restenosis after
coronary angioplasty have become an important field of
investigation in interventional cardiology. In general, the
early results of medical treatments and interventions are
relatively simple to assess, but the long-term studies fre-
quently prove more difficult to evaluate and, historically,
often have been unreliable. Early or preliminary results
often have been misleading and frequently contradict those
of well controlled definitive studies. It appears that innova-
tors and exponents of new treatments may allow their
enthusiasm to compromise their objectivity. Therefore, it is
important that any new technique or pharmacologic treat-
ment is assessed objectively using a methodology with
known reproducibility and in which the technical limitations
are known and understood.
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Although numerous articles have addressed the problem
of restenosis in the clinical setting, many defining certain
factors associated with restenosis and possible interventions
to reduce the incidence of restenosis, there is surprisingly
little consensus. Most of the discrepancies can be attributed
to three factors: 1) the selection of patients, 2) the method
of analysis, and 3) the definition of restenosis employed.
This review shows how these three factors influence the
outcome and conclusions of restenosis studies.
(] Am Coil Cardiol1990;15:491-8)
Over the past 2 to 3years, there has been a rapid increase
in new devices and techniques designed to augment or
replace conventional balloon angioplasty. With the progres-
sive improvement in the immediate success rate and com-
plication rate of the conventional procedure, it has become
more difficult to demonstrate the additional efficacy of new
devices and interventions. Any improvement in the immedi-
ate results may be, as it was with coronary artery bypass
surgery in the past, misleading and, therefore, the attention
of investigators has rightly turned from the immediate results
to the long-term outcome. Restenosis after coronary angio-
plasty, a recognized late complication in 25% to 35% of cases
since the introduction of the procedure in 1977 (1), remains
its main limitation.
Despite the established importance of this topic, there has
been no consensus on how these studies should be per-
formed, with widely differing methodologic approaches giv-
ing diverse and conflicting results. Although the long-term
clinical outcome will remain important in any assessment,
the most objective means of assessing restenosis following
angioplasty is by carefully controlled coronary angiography
at the time of the procedure and at a defined follow-up time.
In the past the visual estimation of the angiographic films has
been used, but a consensus is now beginning to emerge that
0735-1097/90/$3.50
492 BEATT ET AL.
NEW STANDARDS FOR RESTENOSIS STUDIES
JACC Vol. 15, No.2
February 1990:491-8
Table 1. Studies Addressing the Incidence of Coronary Restenosis
Patients
Interval (mo)
First Author % PTCA to %
and Ref Year Total Follow-Up Follow-Up Restenosis Criterion Restenosis
Meyer (22) 1983 70 90 6 AS >85% 20
Thorton (5) 1984 248 72 6-9 NHLBI4 31
Holmes (7) 1984 665 84 6.2 NHBLI4 34
Kaltenbach (14) 1985 356 94 5.6 DS <20% of pre-PTCA 12
Levine (13) 1985 100 92 6 NHLBI4 40
Corcos (8) 1985 92 100 8.2 >70% DS at follow-up 18.5
Leimgruber (6) 1986 1758 57 7 NHLBI4 30
Bertrand (23) 1986 229 Not reported 7 NHLBI4 32
Vandormael (3) 1987 129 62 7 ~20% reduction and 33
~50% DS
Studies addressing the timing and incidence of restenosis
Serruys (9) 1988 400 85 I ~0.72 mm 0.9
2 ~0.72 mm 12.4
3 ~0.72 mm 22.6
4 ~0.72 mm 25.5
Nobuyoshi (2) 1988 185 81 24 h NHLBI4 14.6
229 100 I NHLBI4 12.7
219 % 3 NHLBI4 43.0
149 65 6 NHLBI4 49.4
AS = % area stenosis; DS = % diameter stenosis (mm); NHLBI 4 = criterion 4 of the National Heart. Lung. and Blood Institute (loss of ~50% of gain);
Ref = reference.
recognizes the limitations of this approach. The use of a
quantitative angiographic measuring system for assessing
both the immediate and the long-term results of therapeutic
interventions such as angioplasty appears mandatory.
Methodologic Considerations
Currently there are many studies on coronary restenosis
reported that are distinguished by their lack ofconsistency in
their methodologic approach, their definition of restenosis
and the reported factors influencing restenosis (Table 1).
These studies are demanding in terms of time and financial
resources and are also demanding on the patient because, at
least for the time being, there is a need for repeat angiogra-
phy even if the patient is asymptomatic. This is because of
the reported incidence of silent restenosis, which may be as
high as 33% if a sensitive enough index is used (2). Particu-
larly with studies that look at the impact of a new interven-
tion on restenosis, it is important that their design is capable
of showing the effect of the intervention, if indeed one exists.
Many of the studies published so far have failed to be
sufficiently exacting to form a basis for their conclusions. In
order to improve the situation, there are in principle three
areas that need to be addressed:
1. Study population. If the results are intended to apply to
the angioplasty population, then the study population must
reflect this. This means a high angiographic follow-up rate
with individual patient's time for restudy being predeter-
mined at the time of angioplasty, and not influenced by the
recurrence of symptoms or the anatomy of the lesion after
angioplasty. This will avoid a selection bias of symptomatic
patients or patients with borderline postangioplasty results.
It can be estimated that if a 30% reduction in the
restenosis rate is to be realized at the 0.05 significance level,
then in a double-blind randomized study 400 patients will be
needed in each of the placebo and active treatment groups.
For a 50% reduction in restenosis rate, 150 patients will be
needed in each group.
2. A well validated system of analysis with known accu-
racy and variability should be employed. The use of a visual
percent diameter stenosis measurement with its inherent
variability precludes meaningful results, and edge tracing by
hand or other techniques that can produce values not phys-
iologically possible are also unacceptable.
3. The measured variables must be chosen so as to reflect
the restenosis process and distinguish between the results of
angioplasty and this process. The conventional assessment
of percent diameter stenosis is not sufficiently discriminating
to do this, because, when there is a concomitant decrease in
the reference or normal diameter of the vessel, a smaller
lumen may have a larger measured percent diameter stenosis.
Angiographic Definitions of Restenosis
Limitations of criteria to define restenosis. The definition
of restenosis of choice has been the subject of much debate,
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Figure 1. Shown in terms of cross-sectional area are two possible
outcomes of an initially severe lesion after coronary angioplasty
(PTCA). On the left, the lesion before angioplasty with a 70%
diameter stenosis (area stenosis = 91%). Middle, a good result,
represented by the upper profile leads to a 15% diameter stenosis
(area stenosis = 28%). At follow-up (right), there has been a 42%
change in the area of stenosis represented by the shaded area in the
top circle. Although there is a considerable increase in the plaque
cross-sectional area, the follow-up diameter stenosis is only 45%
and, therefore, using the criterion of >50% diameter stenosis at
follow-up, this is designated as not being a restenosis. In contrast,
the lesion represented on the bottom, which is successfully dilated,
but to a lesser degree (45% diameter stenosis after angioplasty), will
be designated as restenosis if there is even a small deterioration in
the plaque area (change in diameter stenosis of 10%) resulting in a
follow-up diameter stenosis of 55% (percent diameter stenosis/
percent area stenosis).
and there is currently no satisfactory definition that takes
into account both the functional and the angiographic out-
come of the patient after angioplasty. The confusion and
controversy that surround the subject of restenosis are
essentially due to four factors:
1) Many angiographic definitions try to combine the
angiographic outcome with a clinical outcome. The known
discrepancy between these two variables means that this
objective will not be realized, particularly in multivessel
disease (3).
2) A single "stenosis" measurement should not be con-
fused with a measurement of "restenosis," which should
represent the change in stenosis severity.
3) Criteria that are defined by a cut-off value at follow-up
or that are biased by the improvement in lesion diameter
obtained at angioplasty will preselect those lesions with a
less satisfactory result postangioplasty. The definition of a
;:::50% diameter stenosis at follow-up is used to illustrate this
point in Figure 1.
4) Definitions based on percent diameter stenosis mea-
surements may fail to identify lesions undergoing significant
deterioration. These criteria are chosen to reflect the change
in minimal luminal diameter in relation to the so-called
normal diameter of the vessel in the immediate vicinity of the
obstruction. It also assumes that this normal diameter (or the
reference diameter) of the vessel, proximal or distal to the
obstruction, does not change either as a result of angioplasty
or during the immediate follow-up period when restenosis of
the dilated lesion is a well recognized phenomenon. Quanti-
tative angiographic studies have shown this premise to be
false. This seriously questions the use of percent diameter
stenosis as the only index of restenosis (2,4).
Figure 2 illustrates how the choice of reference diameter
may influence the assessment of restenosis in what is a
relatively simple segment to analyze. The choice of refer-
ence diameter, whether interpolated, proximal or distal, has
little effect on the percent diameter stenosis in the examples
before (Fig. 2A) or after (Fig. 2B) angioplasty because the
reference diameter is similar in all cases. In contradistinc-
tion, the choice of reference diameter is highly relevant
to the determination of the percent diameter stenosis at
follow-up (Fig. 2C), largely because of the discrepancy
between the reference diameter proximal to the stenosis
and the one distal to it. The "moving baseline" created
by the fact that the reference diameter may decrease
means that lesions that should be regarded as restenosis may
not be.
Criteria of restenosis in current use. What is the rationale
for the restenosis criteria in current use? Most are entirely
arbitrary, some are based on doubtful logic and some,
although of some relevance for visual estimation of percent
diameter stenosis, are unrealistic when applied to the more
accurate values obtained from quantitative angiography.
The definitions of restenosis used in major restenosis
studies are:
I. Loss of at least 50% of the initial gain achieved at
angioplasty (5).
2. A return to within 10% of the preangioplasty stenosis
diameter (6).
3. An immediate postangioplasty stenosis diameter of
<50% that increases to ;:::50% at follow-up (6,7).
4. As for 3, but for a stenosis diameter ;:::70% at follow-up
(8).
5. Deterioration of 0.72 mm in minimal luminal diameter
or greater from immediately postangioplasty to follow-
up (9).
6. Deterioration of 0.5 mm in minimal luminal diameter
or greater from immediately postangioplasty to follow-
up (2).
Examining the commonly used definition of;:::50% steno-
sis diameter at follow-up. This is based historically on the
physiologic concept of coronary flow reserve and is taken
because it represents the approximate value in animals with
normal coronary arteries at which a blunting of the hyper-
emic response occurs (10). Although this value may be of
45% / 70%
55% /80%
follow-up
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Figure 2. Single frame angiograms of a proximal
left anterior descending artery stenosis. A, predi-
lation (PRE-PTCA), B, postdilation (POST-PTCA)
and C at follow-up. Quantitative coronary analysis
was performed using a coronary angiography anal-
ysis system. The arterial boundaries detected by
the system are shown on the angiogram and below
the diameter function curve derived from these
contours. The example illustrates the importance
of the choice of reference diameter, the fact that
the dilated but nonstenotic coronary artery may be
involved in the restenosis process, and the value of
the interpolated reference diameter for calculating
the appropriate diameter stenosis. A, Before angio-
plasty, the lesion is relatively easy to analyze. The
segments proximal and distal to the stenosis are of
similar caliber and the lesion is relatively discrete,
so that its length can easily be defined on the
diameter function curve. B, After angioplasty,
there is a satisfactory result, the diameter stenosis
decreasing from 59% to 36% (area stenosis from
83% to 59%). C, At follow-up, the result is very
dependent on the method of analysis. The artery
proximal to the stenosis has already been involved
in the restenosis process; if this is chosen as a
reference diameter (left), a 42% diameter stenosis
is obtained (no "restenosis"). The distal portion is
of a larger caliber than the proximal portion; if it is
chosen as a reference diameter (middle), the result
is a 62% diameter stenosis ("restenosis"). If the
interpolated technique is used (rigbt), the reference
diameter is similar to the postangioplasty value,
and a 58% diameter stenosis is obtained that accu-
rately reflects what is happening between the post-
angioplasty result and the follow-up. Even with
this high quality angiogram of a well visualized
segment with a discrete stenosis, there are prob-
lems in obtaining accurate and realistic results.
USER DEFINED PROXIMAL USER DEFINED DISTAL INTERPOLATED
some relevance in determining a significant stenosis in
human atherosclerotic vessels, it tells us nothing about the
way the lesion has behaved since the angioplasty procedure.
It is clear from Figure 1 that no criterion defining the
restenosis as such can include the second example and not
the first. Similar arguments concerning a bias in selection
can be applied to the other commonly used definition of a
loss >50% of the gain.
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Figure 4. Incidence of restenosis (REST) according to three criteria
in the first 150 days after angioplasty derived from the patient group
with 490 successfully dilated lesions shown in Figure 3. Abbrevia-
tions in Figure 3.
Figure 3. The number of lesions fulfilling three restenosis criteria,
taken from a group of 490 lesions measured at follow-up within 6
months. The total number of lesions that fulfill each criterion are
shown under the criteria, and those lesions fulfilling that criterion
and none other are enclosed by only one circle. Lesions included by
any two criteria are enclosed by two circles, and lesions that fulfill
all three criteria (n = 43) are enclosed by all three circles. It can be
seen that lesions that are designated as restenosis are highly
dependent on the criteria for restenosis employed. NHLBI4 =
criterion 4 of the National Heart, Lung, and Blood Institute: loss of
>50% of the gain at angioplasty. ;::50% DS = ;::50% diameter
stenosis at follow-up. ;::0.72 mm = ;::0.72 mm change from postan-
gioplasty to follow-up.
to 52% (2,5,6,9,13). On the other hand, 2:50% diameter
stenosis at follow-up will tend to give a lower incidence of
restenosis because lesions that deteriorate significantly, but
remain within the 0 to 49% range, are not designated as
restenosis. Of the two studies with larger numbers that
document the change in minimal luminal diameter, only one
uses this value to derive a restenosis value of 26% at 4
months (9).
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Incidence of Restenosis
Role of defined criteria of restenosis. In the same way as
the method of analyzing an angiographic frame will influence
the measurement of percent diameter stenosis, so it will
influence the restenosis rate. However, the factor that most
influences the rate is the definition of restenosis used. Figure
3 shows the number of lesions fulfilling three criteria of
restenosis: although 43 of the lesions included by at least one
criterion are included by all three, 32% of those included in
one criterion ("a loss of greater than half the gain") are not
included in either of the other two. Despite this discrepancy,
the incidence of restenosis is not too dissimilar, ranging from
21% to 34% (Fig. 4). What should be clear is that a similar
incidence of restenosis with different criteria may be defining
different populations. This point has particular relevance
when determining the risk factors for restenosis: if restenosis
cannot be reliably determined, then it is unlikely that the
associated risk factors will be identified. The most sensitive
index of restenosis in common use is that of a loss of 2:50%
of the gain, with reported incidence rates ranging from 16%
New restenosis criteria based on quantitative angiography.
As a result of quantitative angiographic studies, a new
concept for defining restenosis criteria based on the change
in minimal luminal diameter has been introduced (9). The
change in this value from postangioplasty to follow-up can
be expected to give a good quantitative measurement of the
degree of restenosis. The restenosis criterion or the cutoff
point dividing the restenosis group from the nonrestenosis
group is then derived by determining the variability of
measurement (1 SD of the difference in means) of the same
lesion taken from separate catheter sessions. Twice the
variability (95% confidence intervals) defines with reason-
able certainty those lesions that have undergone significant
deterioration from those that have not. Reiber et al. (11)
found this value to be 0.72 mm on the basis of angiograms
taken 90 days apart, whereas Nobuyoshi et al. (2), using a
different measurement system, have taken 0.5 mm on the
basis of angiograms taken 7 to 10 days apart. It is important
to realize that the variability will be considerably greater for
angiograms taken from repeat catheterization sessions, as
opposed to repeat angiograms from the same session (11),
something that has not been appreciated by all investigators
using this methodology (12).
Criteria based on the absolute change in minimal luminal
diameter are nevertheless limited because they make no
attempt to relate the extent of the restenosis process to the
size of the vessel. What may be a significant increase in
plaque area in a 1.5 mm diameter vessel may be of no
hemodynamic consequence in a larger vessel of 3.5 mm.
Studies need to be undertaken to assess the variability of
measurement in different diameter vessels, and a "sliding
scale" criterion created that adjusts for vessel size.
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Role of quantitative angiography. The use of quantitative
angiography has given valuable insight into the problem of
defining an incidence of restenosis. It has been demonstrated
that the restenosis process takes place, to some extent, in
most of the lesions dilated and, furthermore, it takes place
not only in the stenotic portion, but also in the dilated but
nonstenotic segments (4). This observation in itself demands
the use of a measurement system that will define the change
in the minimal luminal diameter independent of the change in
the "reference diameter."
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problem of restenosis, it has not proved practical in large
studies. The technique is promising, but the number of
lesions that can be analyzed effectively by this technique is
limited, and the use of the videodensitometric technique
would mean that a significant number of patients undergoing
routine angioplasty (> 10%) would be excluded from resteno-
sis studies. Future developments may mean that this
method, which is potentially easier to perform and requires
only one angiographic projection to obtain a three-dimen-
sional representation, will become the method of choice for
restenosis studies.
Figure 5. Serial changes in the absolute diameter of normal (open
circles) and stenotic (closed circles) segments after coronary angio-
plasty (PTCA) for three follow-up groups. Group I = 3 month
angiographic follow-up, Group II = 6 month angiographic follow-up,
Group III = I year angiographic follow-up. The change in both the
normal (0) and stenotic (e) segments with time are illustrated. Most
of the deterioration in the stenotic segments occurs between I and 3
months, whereas there is a less pronounced steady deterioration in
the nonstenotic segments up to 6 months. (Reprinted with permis-
sion from Nobuyoshi et al. [2]).
b) Grcup DN=185
Timing of Restenosis
It has been clear for some time that restenosis most often
takes place within the first 6 months after dilation (7,14).
Further progression after this time is unusual, with lesion
improvement or deterioration occurring in a small number of
instances, a pattern more characteristic of coronary artery
disease in general (15-17). Recently two reported studies
(2,9) performing follow-up angiography at different prese-
lected follow-up intervals gave remarkably similar results
and showed more precisely how the lesion behaves after
angioplasty. Early after angioplasty, within 30 min, "recoil"
may take place, which in principle should be regarded as a
separate problem from that of the restenosis (Fig. 5). This
decrease in the luminal diameter may be exaggerated by a
vasoconstrictive component if vasodilators are not adminis-
trated after the angioplasty procedure. The recoil, together
with remodeling and possibly thrombus formation, results in
"restenosis" in 11% to 16% of the lesions in the first 24 h
(using the National Heart, Lung, and Blood Institute defini-
tion 4 of restenosis) (2). It then appears that healing and
remodeling may lead to improvement in an appreciable
number of lesions, so that at 30 days the restenosis rate lies
between 6% and 13%. Between 1and 3 months, most lesions
that will develop restenosis do so, with the restenosis rate
reaching 25% to 37% (Fig. 6). A small number may show
further progression between 4 and 6 months. It seems likely
that the restenosis process begins early and is progressive
over the first 3 to 4 months.
The limitations of even the most accurate measurement
systems mean that these early changes are not detected
early, and it is not until substantial progression takes place at
3 months that the process is fully recognized. This early
change has been shown in animals, with evidence of smooth
muscle proliferation as early as 7 to 14 days after dilatation
(18). This same process has been identified in at least 7
postmortem hearts (19-21) that were examined over a period
of 17 to 150 days after angioplasty.
Videodensitometric Analysis
Although videodensitometric analysis has been advo-
cated as the method of choice for studies addressing the
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Risk Factors for Restenosis
Identifying the risk factors. There are no studies using
quantitative coronary angiography that report on the risk
factors in large numbers of patients. There are some factors
relating to the restenosis process that have been identified
and confirmed in more than one study. These include a
proximal left anterior descending coronary artery stenosis, a
totally occluded vessel before angioplasty, the presence of
collateral vessels supplying the distal part of the dilated
coronary artery and associated insulin-dependent diabetes.
Factors that relate to the success of the angioplasty, such as
a residual stenosis >30% or 40%, with current knowledge
should not be considered as risk factors for "restenosis."
For most of the other described risk factors, there are as
many studies that do not as studies that do identify a
particular factor. No procedure-related factor, that would
allow the operator to modify the way angioplasty is per-
formed has yet been identified, and no pharmacologic inter-
vention has been able to show a reduced rate of restenosis.
Quantitative angiography offers the possibility of objective
measurement of lesion morphology, such as length of lesion
and eccentricity, and when this more objective information
becomes available, then perhaps it will be possible to iden-
tify lesion-related factors associated with restenosis.
Role of quantitative angiography in evaluating new proce-
dures and interventions. To date, quantitative coronary
angiography has been used in a limited number of studies
addressing the problem of restenosis. It has already provided
valuable insight into the restenosis problem and has identi-
fied some of the sources of confusion surrounding this topic.
It seems likely that, with better measurement systems,
particularly those that become on-line in the catheterization
laboratory, it will be easier to perform these studies, and
with more reliable data in smaller numbers of patients, the
effect of various interventions to prevent restenosis will be
assessed more accurately and more efficiently. Currently
there is a wide variety of revascularization devices, proce-
dures and pharmacologic interventions under investigation,
Figure 6. Individual minimal luminal diameter (mm) after coronary
angioplasty (YfCA) compared with the control angiographic study
for three different groups at 30, 60 and 90 days. The two solid lines
on either side of the identity line correspond to the long-term
variability (0.36 mm) of repeat measurement for this variable (5).
This variability is I standard deviation of the difference in means of
duplicate angiographic measurements. Therefore, 2standard devia-
tions (2 x 0.36 = 0.72 mm) define the 95% confidence limits for
lesion progression or regression. The lesions showing progression or
regression is represented by closed circles, and the numbers are
shown in the brackets in the left upper and right lower comers.
and of crucial importance in their evaluation will be the
restenosis rate associated with each of these strategies. It is
already clear that a meaningful comparison among the
various strategies and evaluation of their relative merits is
not possible because of a lack of standardization of method-
ology and lack of objectivity. In the future, we should
demand that quantitative analysis be employed in important
studies addressing the long-term outcome of new coronary
interventions, so that the present confusion is not perpetu-
ated.
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